Navigation Links
Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
Date:8/19/2010

SAN FRANCISCO, Aug. 19 /PRNewswire/ -- Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer, today announced the closing of a fully subscribed private placement financing with aggregate gross proceeds of approximately $8.6 million.

Proceeds from this transaction will be used to advance the Company's oncology product platform, led by JX-594, a novel oncolytic agent that has demonstrated promising antitumor activity in Phase 1 and Phase 2 clinical trials.

"This important round of financing provides us with funds necessary to continue to advance our pipeline of promising oncology products through clinical development and to achieve a number of corporate and clinical milestones.  This includes the completion of the ongoing JX-594 Phase 2 clinical trials currently underway for patients with liver cancer and colorectal cancer," said David H. Kirn, M.D., president and chief executive officer of Jennerex.  "We appreciate the support from many of our existing stockholders as well as a number of new important investors who chose to participate in this successful financing."

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer.  The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combination with sorafenib.  Prior, published studies designed to establish dose levels and the safety profile of JX-594 have shown its ability to selectively target a variety of common cancer tumor types.  JX-594 and other product candidates under development are designed to attack cancer tumors through three diver
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
2. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
3. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
6. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
7. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
8. Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
9. DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management
10. Resverlogix Completes Dosing for ASSERT Trial
11. Xybion Completes Acquisition of Stelex and Vital-Path, Leaders in Business Process Software and Consulting Services for Regulated Industries, from GE Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... PA (PRWEB) January 14, 2014 Date: Friday, ... , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... national nonprofit organization solely dedicated to finding a cure for ... affected worldwide, will host its annual Crystal Ball on Friday, ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
(Date:1/14/2014)... 2014 The largest international professional organization of ... therapeutic derivatives thereof has endorsed an educational program ... the challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... fruit fly and roundworm,s functional genomic elements: DNA sequences in ... are turned on and off at various times in different ... Human Genome Project, the genomes of the fruit fly, ... are powerful models for understanding human biology and disease, ...
... 22, 2010 Pathfinder LLC, a private biotechnology company ... cell damage ("Pathfinder"), and SyntheMed, Inc. (OTC Bulletin Board: ... the "Company"), today announced that they have entered into ... renamed  "Pathfinder Cell Therapy, Inc." and the combined company ...
... Inc. (Nasdaq: NVAX ) and scientists at ... Trudy Morrison, published in the January 2011 issue of ... novel virus-like particle (VLP) vaccine candidate against respiratory syncytial ...  This vaccine candidate has been created with technology that ...
Cached Biology Technology:Scientists reveal how biological activity is regulated in fruit fly and roundworm genomes 2Scientists reveal how biological activity is regulated in fruit fly and roundworm genomes 3Scientists reveal how biological activity is regulated in fruit fly and roundworm genomes 4Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 2Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 3Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 4Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 5Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 6NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate 2NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate 3NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate 4
(Date:4/17/2014)... way the immune system may fight cancers and viral ... cells to treat illness. , The research, in mice, ... "neighborhood police" specialized squads of defenders that patrol ... entire city, the body. , Scientists at Washington University ... the liver, skin and uterus each has dedicated immune ...
(Date:4/17/2014)... of our ideas about domestication derive from Charles ... by British animal-breeding practices during the 19th century, ... improvement. , It is from Darwin that ... of captive animals from wild species and total ... But animal management in this industrial setting has ...
(Date:4/16/2014)... Florida State University researchers have identified a new ... bone density and muscle mass with obesity. , "It ... were the better your bones would be because the ... Hazel Stiebeling Professor of Nutrition at Florida State. "But, ...
Breaking Biology News(10 mins):Some immune cells defend only 1 organ 2The story of animal domestication retold 2The story of animal domestication retold 3The story of animal domestication retold 4Researchers: Obesity can amplify bone and muscle loss 2
... A new study from Boston University School of Medicine ... (iPS) cells in an experimental model were not rejected ... published online in Cell Stem Cell , demonstrates ... types that could offer treatment for a wide range ...
... Research Institute (TSRI) have been awarded approximately $1.2 million ... the National Institutes of Health to identify, test and ... of diseases, including rheumatoid arthritis, heart disease and several ... director in TSRI,s Translational Research Institute, and Peter S. ...
... German . , The detector combines near-unity ... very low error rate. The results have been published ... and reliable single-photon detectors are among the most sought-after ... yet reached maturity for practical application. Physicist Dr. Wolfram ...
Cached Biology News:BUSM study shows potential of differentiated iPS cells in cell therapy without immune rejection 2Grant to fund development of drug candidates for rheumatoid arthritis, neurodegenerative disorders 2Quantum communication: Each photon counts 2